EGFR-Mutant NSCLC After WCLC 2026: Frontline Strategy, Risk-Adapted Intensification, and Unmet Needs After Progression

In this OncLive Peer Exchange filmed at the World Conference on Lung Cancer 2026, a panel of thoracic oncology specialists tackles the rapidly evolving treatment landscape for EGFR-mutant non-small cell lung cancer from frontline decision-making through progression and beyond. Across eight episodes, the panel covers how to choose between monotherapy and combination regimens, how tumor features like brain metastases and TP53 co-mutation shape intensification decisions, what new data from key trials mean for adjuvant and frontline practice, how to approach resistance at progression, and where the field is headed for historically underserved populations like exon 20 insertion patients. With a focus on practical, individualized decision-making and real-world applicability, this program delivers clinically grounded insights for oncologists managing this disease at every practice setting.